CRNX Annual CFO
-$166.31 M
-$51.10 M-44.36%
31 December 2023
Summary:
As of January 22, 2025, CRNX annual cash flow from operations is -$166.31 million, with the most recent change of -$51.10 million (-44.36%) on December 31, 2023. During the last 3 years, it has fallen by -$104.28 million (-168.12%). CRNX annual CFO is now -2941.46% below its all-time high of -$5.47 million, reached on December 31, 2016.CRNX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRNX Quarterly CFO
-$62.82 M
-$17.21 M-37.72%
30 September 2024
Summary:
As of January 22, 2025, CRNX quarterly cash flow from operations is -$62.82 million, with the most recent change of -$17.21 million (-37.72%) on September 30, 2024. Over the past year, it has dropped by -$21.48 million (-51.97%). CRNX quarterly CFO is now -2756.89% below its all-time high of -$2.20 million, reached on June 30, 2017.CRNX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRNX TTM CFO
-$199.81 M
-$21.48 M-12.05%
30 September 2024
Summary:
As of January 22, 2025, CRNX TTM cash flow from operations is -$199.81 million, with the most recent change of -$21.48 million (-12.05%) on September 30, 2024. Over the past year, it has dropped by -$36.81 million (-22.58%). CRNX TTM CFO is now -8490.33% below its all-time high of -$2.33 million, reached on March 31, 2017.CRNX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRNX Cash From Operations Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -44.4% | -52.0% | -22.6% |
3 y3 years | -168.1% | -52.0% | -22.6% |
5 y5 years | -754.6% | -52.0% | -22.6% |
CRNX Cash From Operations High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -87.7% | at low | -363.9% | at low | -143.5% | at low |
5 y | 5-year | -258.6% | at low | -413.7% | at low | -330.8% | at low |
alltime | all time | -2941.5% | at low | -2756.9% | at low | -8490.3% | at low |
Crinetics Pharmaceuticals Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | -$62.82 M(+37.7%) | -$199.81 M(+12.0%) |
June 2024 | - | -$45.62 M(-13.7%) | -$178.33 M(-0.1%) |
Mar 2024 | - | -$52.86 M(+37.2%) | -$178.44 M(+7.3%) |
Dec 2023 | -$166.31 M(+44.4%) | -$38.52 M(-6.8%) | -$166.31 M(+2.0%) |
Sept 2023 | - | -$41.34 M(-9.6%) | -$163.00 M(+1.8%) |
June 2023 | - | -$45.73 M(+12.3%) | -$160.14 M(+12.5%) |
Mar 2023 | - | -$40.72 M(+15.7%) | -$142.38 M(+23.6%) |
Dec 2022 | -$115.20 M(+30.0%) | -$35.21 M(-8.5%) | -$115.20 M(+12.0%) |
Sept 2022 | - | -$38.48 M(+37.5%) | -$102.90 M(+14.2%) |
June 2022 | - | -$27.98 M(+106.6%) | -$90.09 M(+9.8%) |
Mar 2022 | - | -$13.54 M(-40.9%) | -$82.06 M(-7.4%) |
Dec 2021 | -$88.59 M(+42.8%) | -$22.90 M(-10.8%) | -$88.59 M(+8.5%) |
Sept 2021 | - | -$25.67 M(+28.7%) | -$81.63 M(+10.4%) |
June 2021 | - | -$19.95 M(-0.6%) | -$73.96 M(+5.9%) |
Mar 2021 | - | -$20.07 M(+25.9%) | -$69.86 M(+12.6%) |
Dec 2020 | -$62.03 M | -$15.94 M(-11.5%) | -$62.03 M(+4.2%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2020 | - | -$18.00 M(+13.6%) | -$59.54 M(+8.0%) |
June 2020 | - | -$15.86 M(+29.6%) | -$55.14 M(+6.3%) |
Mar 2020 | - | -$12.23 M(-9.1%) | -$51.85 M(+11.8%) |
Dec 2019 | -$46.38 M(+138.4%) | -$13.45 M(-1.2%) | -$46.38 M(+19.1%) |
Sept 2019 | - | -$13.61 M(+8.3%) | -$38.94 M(+25.5%) |
June 2019 | - | -$12.57 M(+85.9%) | -$31.03 M(+36.0%) |
Mar 2019 | - | -$6.76 M(+12.5%) | -$22.81 M(+17.2%) |
Dec 2018 | -$19.46 M(+105.3%) | -$6.01 M(+5.6%) | -$19.46 M(+21.9%) |
Sept 2018 | - | -$5.69 M(+30.9%) | -$15.96 M(+25.6%) |
June 2018 | - | -$4.35 M(+27.7%) | -$12.71 M(+20.4%) |
Mar 2018 | - | -$3.41 M(+35.7%) | -$10.56 M(+11.4%) |
Dec 2017 | -$9.48 M(+73.4%) | -$2.51 M(+2.8%) | -$9.48 M(+36.0%) |
Sept 2017 | - | -$2.44 M(+11.1%) | -$6.97 M(+54.0%) |
June 2017 | - | -$2.20 M(-5.5%) | -$4.53 M(+94.5%) |
Mar 2017 | - | -$2.33 M | -$2.33 M |
Dec 2016 | -$5.47 M | - | - |
FAQ
- What is Crinetics Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals annual CFO year-on-year change?
- What is Crinetics Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals quarterly CFO year-on-year change?
- What is Crinetics Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals TTM CFO year-on-year change?
What is Crinetics Pharmaceuticals annual cash flow from operations?
The current annual CFO of CRNX is -$166.31 M
What is the all time high annual CFO for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high annual cash flow from operations is -$5.47 M
What is Crinetics Pharmaceuticals annual CFO year-on-year change?
Over the past year, CRNX annual cash flow from operations has changed by -$51.10 M (-44.36%)
What is Crinetics Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of CRNX is -$62.82 M
What is the all time high quarterly CFO for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high quarterly cash flow from operations is -$2.20 M
What is Crinetics Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, CRNX quarterly cash flow from operations has changed by -$21.48 M (-51.97%)
What is Crinetics Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of CRNX is -$199.81 M
What is the all time high TTM CFO for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high TTM cash flow from operations is -$2.33 M
What is Crinetics Pharmaceuticals TTM CFO year-on-year change?
Over the past year, CRNX TTM cash flow from operations has changed by -$36.81 M (-22.58%)